Trial Search Results

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Stanford is currently accepting patients for this trial.

Lead Sponsor:


Stanford Investigator(s):


  • Drug: Bimatoprost SR
  • Other: Sham: Applicator Without Needle
  • Drug: Active Comparator: Timolol 0.5%
  • Drug: Timolol Vehicle (placebo)


Phase 3


Inclusion Criteria:

- Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes
require IOP-lowering treatment.

Exclusion Criteria:

   - Previous enrollment in another Allergan Bimatoprost SR Study

   - Eye surgery (including cataract surgery) and/or any eye laser surgery within the past
   6 months in the study eye

   - Anticipated need for laser eye surgery within the first 52 weeks of the study duration

   - History of glaucoma surgery

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mariana Nunez